Afficher la notice abrégée

ESO guideline for the management of extracranial and intracranial artery dissection

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDEBETTE, Stephanie
dc.contributor.authorMAZIGHI, Mikael
dc.contributor.authorBIJLENGA, Philippe
dc.contributor.authorPEZZINI, Alessandro
dc.contributor.authorKOGA, Masatoshi
dc.contributor.authorBERSANO, Anna
dc.contributor.authorKORV, Janika
dc.contributor.authorHAEMMERLI, Julien
dc.contributor.authorCANAVERO, Isabella
dc.contributor.authorTEKIELA, Piotr
dc.contributor.authorMIWA, Kaori
dc.contributor.authorSEIFFGE, David
dc.contributor.authorSCHILLING, Sabrina
dc.contributor.authorLAL, Avtar
dc.contributor.authorARNOLD, Marcel
dc.contributor.authorMARKUS, Hugh
dc.contributor.authorENGELTER, Stephen
dc.contributor.authorMAJERSIK, Jennifer J.
dc.date.accessioned2021-12-06T15:15:28Z
dc.date.available2021-12-06T15:15:28Z
dc.date.issued2021-09
dc.identifier.issn2396-9881 (Electronic) 2396-9873 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124003
dc.description.abstractEnThe aim of the present European Stroke Organisation guideline is to provide clinically useful evidence-based recommendations on the management of extracranial artery dissection (EAD) and intracranial artery dissection (IAD). EAD and IAD represent leading causes of stroke in the young, but are uncommon in the general population, thus making it challenging to conduct clinical trials and large observational studies. The guidelines were prepared following the Standard Operational Procedure for European Stroke Organisation guidelines and according to GRADE methodology. Our four recommendations result from a thorough analysis of the literature comprising two randomized clinical trials (RCTs) comparing anticoagulants to anti-platelets in the acute phase of ischemic stroke and twenty-six comparative observational studies. In EAD patients with acute ischemic stroke we recommend using intravenous thrombolysis (IVT) with alteplase within 4.5 hours of onset if standard inclusion/exclusion criteria are met, and mechanical thrombectomy in patients with large vessel occlusion of the anterior circulation. We further recommend early endovascular or surgical intervention for IAD patients with subarachnoid hemorrhage (SAH). Based on evidence from two phase 2 RCTs that have shown no difference between the benefits and risks of anticoagulants versus anti-platelets in the acute phase of symptomatic EAD, we strongly recommend that clinicians can prescribe either option. In post-acute EAD patients with residual stenosis or dissecting aneurysms and in symptomatic IAD patients with an intracranial dissecting aneurysm and isolated headache, there is insufficient data to provide a recommendation on the benefits and risks of endovascular/surgical treatment. Finally, nine expert consensus statements, adopted by 8 to 11 of the 11 experts involved, propose guidance for clinicians when the quality of evidence was too low to provide recommendations. Some of these pertain to the management of IAD (use of IVT, endovascular treatment, and antiplatelets versus anticoagulation in IAD with ischemic stroke and use of endovascular or surgical interventions for IAD with headache only). Other expert consensus statements address the use of direct anticoagulants and dual antiplatelet therapy in EAD-related cerebral ischemia, endovascular treatment of the EAD/IAD lesion and multidisciplinary assessment of the best therapeutic approaches in specific situations.
dc.language.isoENen_US
dc.subject.enExtracranial artery dissection
dc.subject.enCervical artery dissection
dc.subject.enIntracranial artery dissection
dc.subject.enStroke
dc.subject.enSubarachnoid hemorrhage
dc.subject.enEndovascular treatment
dc.subject.enAspirin
dc.subject.enAnticoagulants
dc.subject.enThrombolysis
dc.subject.enMechanical thrombectomy
dc.title.enESO guideline for the management of extracranial and intracranial artery dissection
dc.typeArticle de revueen_US
dc.identifier.doi10.1177/23969873211046475en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34746432en_US
bordeaux.journalEuropean Stroke Journalen_US
bordeaux.pageXXXIX-LXXXVIIIen_US
bordeaux.volume6en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamVINTAGEen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03467656
hal.version1
hal.date.transferred2021-12-06T15:15:31Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Stroke%20Journal&rft.date=2021-09&rft.volume=6&rft.issue=3&rft.spage=XXXIX-LXXXVIII&rft.epage=XXXIX-LXXXVIII&rft.eissn=2396-9881%20(Electronic)%202396-9873%20(Linking)&rft.issn=2396-9881%20(Electronic)%202396-9873%20(Linking)&rft.au=DEBETTE,%20Stephanie&MAZIGHI,%20Mikael&BIJLENGA,%20Philippe&PEZZINI,%20Alessandro&KOGA,%20Masatoshi&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée